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Background/Aims: Pragmatic clinical trials (PCTs) represent an increasingly used strategy for “real-world”
trials. Successful PCTs typically require participation of community-based practices. However, commu-
nity clinicians often have limited interest or experience in clinical research. Many barriers to practice-
based research have been described, but possible motivations to participate among community
practices not active in research have not been well explored. The tendency is for researchers to assume
similar motivations and priorities across all candidate practices. This is not necessarily the case. A better
understanding of the range of reasons clinicians might see for participating in pragmatic trials could be
key to promoting this type of practice-based research.
Methods: Semi-structured interviews were conducted with 30 clinicians and staff members. Half of the
interviewees had experience doing practice-based clinical trials and half did not. Individuals in these two
groups were also diversiﬁed in terms of their practice size and location. Participants were asked about
motivations and barriers to doing practice-based research in the context of a planned osteoporosis
pragmatic clinical trial. Interviews were transcribed, coded, and analyzed.
Results: Barriers identiﬁed for both experienced and not-experienced clinicians and staff members
included: a lack of time, increased paperwork, disruption to work ﬂows, and concern over practice ﬁ-
nances. Similar ﬁndings have been reported in the US, UK, Europe, and Australia. However, regarding
positive motivations of practices to participate, we found systematic differences in attitude between
research-engaged and research-naïve practices that have not been previously reported. The research-
experienced group offered a greater number and variety of reasons to take part than the not-
experienced group. While both groups expressed motivations related to patient care, clinicians and
staff members experienced in practice-based clinical trials were much more likely to cite intellectual,
professional, and societal beneﬁts not envisioned by the other group.
Conclusions: We conclude that clinicians not already participating in practice-based trials may have a
narrower range of motivations than those already participating. The lack of a broader view of possible
beneﬁts to participation may also translate into more obdurate recruiting challenges. These results point
to the need for recruitment, engagement, and messaging approaches differentially tailored to the needs
and interests of non-participating practices.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).nology Policy, World Trade
timore, MD 21202, USA.
. Messner).
n open access article under the CC1. Introduction
Traditional randomized controlled trials (RCTs) often lack
generalizability to routine care settings and fail to account for
heterogeneity in patient characteristics and preferences. [1e4] OneBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of Interviewees and their practices.






Has experience with clinical trials 53%
Has no experience with clinical trials 47%






Solo (1 attending physician) 20%
Has 2 to 4 attending physicians 37%
Has 5 to 7 attending physicians 37%
Has more than 7 attending physicians 7%
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(PCTs) [1,5,6]. PCTs are large RCTs designed to admit variations
more representative of real-life conditions of care than traditional
“explanatory” RCTs in which patient population characteristics,
care setting, care administration, and follow-up are tightly
controlled [7e9]. To capture variations across broad populations
and care settings, PCTs should ideally be conducted across a range
of practice settings, including community-based practices not
typically involved in RCTs.
PCTs have increasingly gained purchase. Programs such as the
NIH Collaboratory (a pilot program to conduct PCTs through a
network of health systems) [10] and the Agency for Healthcare
Research and Quality's Practice-based Research Networks (PBRNs)
[11] have helped to establish the infrastructure and best practices
needed for successful community-based trials. Nevertheless,
important challenges remain. Broad-based participation by many
practices not routinely engaged in research is required for a robust
clinical research enterprise capable of exploring less common
conditions or adverse events across varied community settings. Yet
85% of physicians who participate in clinical trials do not repeat the
experience [2], pointing to a signiﬁcant disconnect between the
expectations of novice clinician-researchers and the current reality
of doing trials.
Further, many practicing clinicians have little interest in
research. While many barriers to involvement have been described
in the literature, the possible motivations to participate among
those not currently active in PCTs have not been well explored. The
tendency is for researchers to assume similar motivations for pro-
spective practices to participate. This is not necessarily the case. A
better understanding of the range of reasons clinicians might see
for participating in pragmatic trials could be key to promoting this
type of practice-based research.
Below we describe a set of interviews in which we asked phy-
sicians and staff members in community practices about barriers to
participating in PCTs and reasons to do so. We found notable dif-
ferences, especially in the motivations to participate in PCTs, be-
tween those who already participate and those who do not. These
results may provide insight into how PCTs can be better planned,
communicated, and implemented for enhanced relevance to, and
recruitment of, community-based practices.
2. Methodology
A total of 30 semi-structured interviews were conducted with
24 physicians and 6 staff members. The interview guide was
designed to inform the development of an iPad-based informed
consent tool in a planned osteoporosis PCT. If successful, the project
would address a key barrier to doing community-based
PCTsdwork ﬂow disruption associated with informed con-
sentdto make practice-based PCTs more practicable. To under-
stand the relative importance of this one barrier to clinicians and
staff (both those already participating in practice-based trials and
those who are not), the interview guide included questions on the
barriers to, and chief reasons to participate in, clinical trials that use
their practices as sites for recruiting, implementation, and data
collection (“practice-based trials”).
Interviewees were recruited through email listservs of the Ala-
bama Practice Based Research Network (APBRN) and the American
Academy of Family Physicians (AAFP). Participating physicians
received $100 and staff members received $50 as honorarium for the
30- to 60- minute interview. Not-experienced prospective in-
tervieweesproved resistant to recruitment. Aftermultiple failed email
appeals, we ultimately identiﬁed and recruited not-experienced
physicians by having network directors speciﬁcally reach out to col-
leagues in the network known to lack practice-based trial experience.The initial recruitment target was 12 experienced and 12 non-
experienced practice members for a total of 24. Among each sub-
group of 12, 6 would ideally be rurally located while another 6
would operate in suburban or urban settings. Differing practice
sizes were also desired across these subgroups. Since we were
soliciting volunteers through a listserv and recruitment was rela-
tively slow, we would not have been able to select speciﬁcally for
practice size or other characteristics without signiﬁcantly
increasing the size and duration of the investigation. For the pur-
poses of the project, this was deemed unnecessary. However,
experienced practice members were initially oversampled in an
effort to encounter volunteers who were non-experienced (before
network directors were asked to assist with recruitment). This
resulted in 30 total interviewees of the composition shown in
Table 1. A ﬁrst set of 9 interviews were accomplished to pilot test
the interview guide and assure that all key topics of interest were
being covered. Then the remainder of the interviews were
completed.
We deﬁned “experienced” clinicians and staff as those who, at a
minimum, had participated in patient recruitment and consent
procedures for clinical trials (whether of pragmatic or explanatory
design). Those having only quality improvement research experi-
ence or experience with observational studies were considered to
be “not-experienced” for the purposes of this study.
Experience status, practice size, and location were determined
through self-identiﬁcation by key informants. Initial identiﬁcation
of experience status for screening purposes was accomplished
through self-identiﬁcation in an electronic response form. The ﬁrst
9 (pilot) interviewees were purposively sampled (i.e., speciﬁcally
selected for interviews [12]) consistent with the criteria used for
the larger group, with practice size and location conﬁrmed through
online research.
Interviews were recorded, transcribed, and coded for analysis.
Development and reﬁnement of codes was accomplished through
collaborative team-based coding (using two coders) and facilitated
by NVivo software [13].3. Results
3.1. Challenges to participating in clinical trials
For our interviewees, chief among the concerns regarding
practice-based PCTs was a possible strain on practice resources.
Half of all interviewees (15, 8 of whom had clinical research
experience as deﬁned above) indicated that ﬁnding time for clinical
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(or was anticipated to be) challenging. Many informants indicated
that that they lacked staff or wished they could hire additional staff
to cover the extra duties for clinical trials. Six out of the 7 in-
terviewees who speciﬁcally cited inadequate stafﬁng were not
experienced with clinical research. Five of these informants said
that they would want the sponsor to help with trial coordination,
either through sharing a “roaming research coordinator”with other
trial sites, or providing resources to hire a part-time coordinator.
Resource-related subthemes included: concern that clinical trial
procedures were disruptive to work ﬂow (3 informants, 2 experi-
enced); possible backlogs in the waiting room (2 informants); and
insufﬁcient ofﬁce space for recruitment and consent (4 in-
formants); and paperwork burdens (7 informants, 4 experienced).
Finances were a concern for 11 informants (6 experienced); of
these, 8 expressed concern that compensation received for doing
clinical trials is insufﬁcient to cover the additional workload
incurred. Another 3 informants said doing clinical trials depletes
revenue because research activities deprive them of time they
could spend with the routine patients who account for the bulk of
their compensation.
Despite these ﬁnancial concerns, some informants saw trial-
based money-making opportunities as ethically suspect, particu-
larly industry-sponsored trials. Although many PCTs are not
industry-funded, industry does sometimes recruit community
practices for trials. One interviewee asked, “Will patients feel like
we're just using them to earn ﬁnancially?”. For this physician, the
answer was doing studies “that beneﬁt the practice, patients, and
staff in someway other than ﬁnancially.” Four other physicians also
voiced a wish to guard against “commercial bias”.
Another ethical concern was conﬂict-of-interest, as noted by 6
interviewees (4 having clinical trial experience). Two informants
were concerned about coercion of patients to participate in studies;
1 said research “interferes” with patient care. One rural non-
experienced clinician said, “I wonder if it hurts my credibility, in
the long run, trying to sell them or trying to offer them to be part of
a study.” The theme of conﬂicting clinician/researcher roles was
articulated most forcefully by an experienced physician in an urban
practice setting. He previously participated in drug and other
intervention trials but discontinued involvement because the
message of the clinical trial recruiter, he said, “is not consistent with
why I want to see them in my ofﬁce. It's not consistent with better
diabetic control, better hypertension control. They're an entirely
different message.”
Practitioner disinterest was a frequent theme in these conver-
sations. A third of all interviewees indicated that the interest level
of colleagues or staff was insufﬁcient or required special incentives.
Although 2 physicians said that clinical trials provided an oppor-
tunity for the staff's professional growth, 4 indicated that their staff
would only see it as an extra burden. “Their needs are more
emergent,” said one clinician, noting that pay incentives could be
helpful. Another clinician said selecting topics relevant to care was
key to motivating his staff. “… for the postpartum study, the nurses
jumped right in because it looked like they were really helping
people, and it was part of care.”
Research relevance, while important to many, was sometimes
insufﬁcient to overcome barriers. Three experienced clinicians indi-
cated that they participated in studies their colleagues ignored. For
one non-participating clinician, research was “always just too much
time and effort with a busy practice.” This interviewee, who was a
rural family practice physician, added that the state university's
medical schoolwasenlisting rural physicians for clinical trials.He saw
this outreach as intrusive and assumed themotivation for trials to be
primarily ﬁnancial. “I know it brings money into the college that
wouldn't exist otherwise, so that seems to be the primary carrot.”Four out of the 9 physicians without experience in clinical trials
noted that they would need support and buy-in from others to
participate in clinical trials; colleagues, administrators, “corporate
hierarchy”, department chiefs, and practice leadership were all
noted as individuals or entities in need of convincing. The concerns
were both ﬁnancial (“my partners [are] strictly looking at the bot-
tom line”) and organizational (“bringing everyone together to see
how … we can modify our schedules”). One informant added that
he needed assistance understanding how to get started, and to
educate administrators on what would be required and why it was
worth doing: “… good help, good education can deﬁnitely help us
incorporate this into our practice.”
3.2. Motivations for participating in clinical trials
Themost commonmotives to participate in practice-based trials
cited by our interviewees revolved around patient-centered or
humanitarian goals. Eight informants indicated that they hoped to
provide direct beneﬁts to the patients through trials and 8 said that
they wanted to create knowledge that was speciﬁcally relevant for
patient care. Other beneﬁts to patients included free access to care,
early access to new therapies, ﬁnding solutions to difﬁcult health
problems, and getting patients more involved in their own care.
Seven interviewees saw conducting clinical trials as a public good
because it created knowledge “for the betterment of society” and
the community.
Professional developmentdthe opportunity to learn something
new, provide educational opportunities for staff, students, resi-
dents, and internsdwas cited as a motivation by 6 informants.
Others said clinical studies “keep things interesting” and provide an
opportunity to be “a part of something bigger than your day-to-day
thing.” Three interviewees also indicated that they believed clinical
trial participation would reﬂect positively on their practices,
providing a competitive edge. It would “show the patients we're on
more of a cutting edge.”
Six informants said that the business model would have towork
to accommodate clinical trials. For 3 of these interviewees, ﬁnancial
gainwas a motivator: “… it's ﬁnancially rewarding if you do it right
and do enough of it.”
Notably, most of the physicians who talked about beneﬁts
beyond patient care or ﬁnances were already participating in
clinical trials. While direct beneﬁts to patients were important for
this group, they were also motivated by creating knowledge for
society or community (6 of 7), or intellectual stimulation (7 of 7), or
professional development (5 of 6). By contrast, physicians not
already participating in trials were less likely to cite thesedor
anydpositive motivations for participation. There were 45 men-
tions of positive reasons to participate in research from the expe-
rienced group vs. only 16 mentions by non-experienced
participants (Table 2). When interviewees who lacked clinical trial
experience did cite reasons to participate, they tended to focus on
direct patient beneﬁts rather than on intellectual or societal
beneﬁts.
4. Discussion
Consistent with our ﬁndings, studies of physician partici-
pation in research in the US, UK, Europe, and Australia iden-
tiﬁed lack of time and unwillingness to take on additional
work as primary barriers. Clinicians say they are overworked
or have too much paperwork [14e21], have limited staff sup-
port [20], and need “protected time” to conduct research [22].
Physicians often said that clinical research will create extra
expenses or labor hours in need of compensation
[14,16,20,22,23]. They noted their lack of research training [16]
Table 2
Reasons to participate in pragmatic clinical trials as offered by experienced vs. non-





Beneﬁts oriented to patient care
Offer free medicine/care 2 0
Offer care they need anyway as part of
study
2 1
Affords more care time with patients who
want it
1 0
Early access to new treatments 3 0
Create knowledge for patient care 6 3
Solutions to difﬁcult patient problems 2 1
Real-world patients in clinical trials 1 2
Get patients involved in own care 2 2
Quality improvement 0 1
Beneﬁts not oriented to patient care
Gain competitive edge in practice 4 1
Financial beneﬁts 4 2
Intellectual stimulation in practice 7 1
Knowledge for beneﬁt of society or
community
6 1
Professional development 5 1
Total reasons cited 45 16
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practice [24].
The literature also reﬂects a concern for some clinicians that
research is incompatiblewith patient care, either due to a perceived
conﬂict in goals [25,26], fear of undermining the doctor-patient
relationship [25], or a sense that the doctor's “primary allegiance
is to the individual patient, with less inclination to participate in
RCTs when there is uncertainty about the best treatment” [27].
These concerns pose a barrier not only to practice-based trials, but
more generally to creation of a “learning healthcare system” in
which systematic learning during patient-clinician encounters
would be routine [28e30].
In response to the barriers noted above, the literature offers
strategies for mitigation, e.g., assuring relevance to clinical practice,
regular feedback to clinicians by study leaders, minimizing impact
on usual clinical care, and compensating clinicians who participate
in research [14,24]. However, our study suggests that it may not
enough to identify the barriers to practice-based research and
design strategies to mitigate them. Little effort has been made to
see if positive motivations for research participation differ in any
systematic way between clinicians already engaged and those who
are not. Our research suggests they do.
This was a small qualitative study not designed to explore these
attitudes in depth. As noted in the methods section, systematic
sampling for speciﬁc subgroup characteristics was not done. So, for
example, the study was not designed to assess quantitatively
whether non-experienced practice clinicians and staff were sys-
tematically different in some other way (e.g., age, specialty, or
training) between the two groups. Nevertheless, the observed dif-
ference between experienced and non-experienced practices ap-
pears to persist across a range of practice settings and sizes. If this
result holds true more generally, it would suggest that the
communication and recruiting strategies needed to attract partic-
ipants to community-based research differ according to the target
audience. Unlike the idealistic colleagues who believe (as one
experienced interviewee said) “you just have to make it work”
because it is worthwhile, non-participating practices may need a
more compelling argument for direct beneﬁt to patientsdnot only
future patients who beneﬁt from knowledge generated, but current
patients who can beneﬁt from enhanced access to care, better
quality of care, more interest in their own care, or other factors.
In addition, more effective engagement strategies are likelyneeded. As noted above, in this study not-experienced physicians
ignored repeated recruitment appeals through PBRN listservs.
Personal appeals from network directors were ultimately required
to recruit these interviewees, andmost of them sat for interviews as
personal favors. Participants such as these are not looking for
research opportunities. It will take more targeted efforts to contact
such practices and achieve meaningful communication on planned
research endeavors. Engaging non-experienced clinicians early in
design and throughout the research process may help to assure
practice-based studies are meaningful to these prospective partic-
ipants [31,32]. It may also help to create strategies for communi-
cating with these clinician-stakeholders not only in recruiting, but
throughout research and dissemination of results.
Notably, informants often made no distinction between prag-
matic and explanatory trial designs in their responses. While this
can be seen as a limitation of the study, it also provides insight into
another potentially important aspect of clinician engagement: ed-
ucation on how a speciﬁc proposed clinical trial may differ from
clinicians' preconceptions of what a “typical” clinical trial entails.
5. Conclusions
For an expanding assortment of large, well-designed PCTs to be
done, the numbers of participating practices must grow. We
conclude that clinicians not already participating in practice-
based trials may have a narrower range of motivations than
those already participating. The lack of a broader view of possible
beneﬁts to participation may translate into more obdurate
recruiting challenges. These results point to the need for recruit-
ment, engagement, and messaging approaches differentially
tailored to the needs and interests of non-participating practices.
Even with these measures, many practices will choose not to
participate. However, as noted earlier, open and transparent
engagement can serve to bolster the conﬁdence of non-
participating practices in the legitimacy and relevance to pa-
tients of the proposed research.
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